Overview
Putnam Associates provides strategy consulting for the life sciences sector, focusing on biopharmaceuticals, diagnostics, and medical devices, and also serves private equity and venture capital clients. Its offerings combine tailored strategic advice and analytical services to guide decisions across the product and franchise lifecycle. The firm differentiates itself through deep industry specialization, long-standing client relationships, and a client-centric approach that justifies premium pricing. Its goal is to be a trusted partner that helps clients maximize value and navigate challenges in development, portfolio strategy, and market access.
Work here?Claim your company
Simplify's take
What believers are saying
- UDG paid up to $88.6 million for Putnam in 2026, validating strategic value.
- Inizio Ignite job postings still use Putnam branding, signaling active hiring and continuity.
- The acquisition expands Putnam's reach into UDG's advisory platform and healthcare client base.
What critics are saying
- UDG Healthcare bought Putnam in 2026, ending standalone independence and tightening oversight.
- Integration into Inizio Ignite risks culture clashes, attrition, and client churn through 2027.
- Consulting demand depends on biopharma budgets; prolonged pipeline cuts hit utilization immediately.
What makes Putnam Associates unique
- Putnam specializes in life-sciences commercial strategy, pricing, reimbursement, and market-access work.
- Its 120-person Boston and San Francisco base gives deep sector focus and senior access.
- Inizio Ignite bundles Putnam with Research Partnership, Vynamic, and STEM for cross-sell reach.
Help us improve and share your feedback! Did you find this helpful?